Physician profile
Parvez Karim
NPI 1275562464
$1,000.97
in general payments reported to CMS, 2019-2025
13 companies · $58.63 in 2025
The $58.63 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $139 · 2021: $176 · 2022: $120 · 2023: $42.75 · 2024: $163 · 2025: $58.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $284.89 | 2019-2025 | |
| Allergan, INC. | $162.09 | 2019-2020 | |
| Amgen INC. | $153.02 | 2019-2020 | |
| Global Blood Therapeutics, INC. | $96.49 | 2020-2021 | |
| Mylan Specialty L.P. | $85.87 | 2024 | Yupelri |
| Pfizer INC. | $48.52 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $45.26 | 2022 | |
| Alpha Cognition USA, INC. | $31.67 | 2025 | Zunveyl |
| Smith+Nephew, INC. | $28.13 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $25.26 | 2022 | |
| Genzyme Corporation | $15.89 | 2021 | |
| Janssen Biotech, INC. | $12.06 | 2021 | |
| Mallinckrodt Hospital Products INC. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parvez Karim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.